Bupivacaine SNB — Competitive Intelligence Brief

Bupivacaine SNB (Bupivacaine SNB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia/Pain Management.

marketed Local anesthetic Voltage-gated sodium channels Anesthesia/Pain Management Small molecule

Target snapshot

Bupivacaine SNB (Bupivacaine SNB) — Pacira Pharmaceuticals, Inc. Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine SNB TARGET	Bupivacaine SNB	Pacira Pharmaceuticals, Inc	marketed	Local anesthetic	Voltage-gated sodium channels
Standard dose oxcarbazepine	Standard dose oxcarbazepine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant; sodium channel blocker	Voltage-gated sodium channels
Standard dose lamotrigine	Standard dose lamotrigine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels; glutamate release inhibition
Articaine hydrochloride 2% solution	Articaine hydrochloride 2% solution	Helsinki University Central Hospital	marketed	Local anesthetic (amide type)	Voltage-gated sodium channels
Levobupivacaine plus sufentanil epidural infusion	Levobupivacaine plus sufentanil epidural infusion	University of Genova	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (levobupivacaine); mu-opioid receptor (sufentanil)
Replacement with Zonisamide	Replacement with Zonisamide	Eisai Inc.	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels, T-type calcium channels
Heavy Bupivacaine	Heavy Bupivacaine	Diskapi Yildirim Beyazit Education and Research Hospital	marketed	Local anesthetic (amide)	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class